ALX Oncology (ALXO) SVP granted 140,000 options at $1.70
ALX Oncology (ALXO) reported an insider equity award.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ALX Oncology (ALXO) reported an insider equity award. On October 14, 2025, the company granted its SVP, Finance and CAO an employee stock option for 140,000 shares of common stock at a $1.70 exercise price, recorded as a grant at $0 price and held directly.
The option vests in two steps: one‑third on April 30, 2026 and the remaining two‑thirds on October 31, 2026. Following the transaction, 140,000 derivative securities were beneficially owned.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) | 140,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. One-third of the shares subject to the option vest on April 30, 2026 and the remaining two-thirds of the option vest on October 31, 2026.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did ALXO disclose in this Form 4?
Who is the reporting person and role at ALXO?
What is the vesting schedule for the options?
How many derivative securities were owned after the transaction?
What was the transaction price and form of ownership?
What type of security underlies the option?
AI-generated analysis. How Rhea-AI works. Not financial advice.